Aarti Industries targets Rs 1,800-2,200 crore EBITDA by FY28

Aarti Industries targets earnings before interest, tax, depreciation and amortisation (EBITDA) of Rs 1,800-2,200 crore in FY28, compared with Rs 1,172 crore reported in FY26. AIL identifies Rs 800-1,200 crore of potential growth from cost optimisation, volume and margin ramp-ups, and capital-expenditure-led projects, with Zone IV projects set to commercialise in FY27.

How does AIL plan to reach its FY28 EBITDA target?

AIL plans to use three EBITDA growth drivers worth Rs 800-1,200 crore over its FY25-FY28 plan: Rs 150-200 crore from cost optimisation, Rs 350-550 crore from volume and margin ramp-up, and Rs 300-450 crore from capital-expenditure-led growth. AIL also says operating leverage and cost initiatives are intended to increase EBITDA beyond the contribution from higher volumes.

Reported EBITDA increased from Rs 984 crore in FY24 to Rs 1,016 crore in FY25 and Rs 1,172 crore in FY26. The FY28 target range is Rs 628-1,028 crore above FY26 EBITDA, while AIL reported Rs 802 crore in H1 FY27.

The FY28F range is AIL's target rather than a reported result. Its three-year outlook calls for consistent volume growth from increased capacities, while Zone IV projects are scheduled to commercialise in FY27 and ramp up over the following 18-24 months.

What cost actions are expected to add to EBITDA?

AIL assigns Rs 150-200 crore of potential EBITDA growth to cost optimisation and describes this programme as majorly completed. Its measures include switching to a back-pressure turbine to improve cogeneration, renewable power phase 2, use of waste-energy streams, and effluent treatment plant cost optimisation.

The programme also includes fixed-cost optimisation, yield improvement, and digital and advanced-analytics-led cost-excellence initiatives. AIL presents these actions separately from the Rs 350-550 crore volume and margin-ramp-up category, identifying operating costs as an independent contributor to the FY28 plan.

AIL's market update shows that cost and margin conditions differ by value chain. Acids-chain margins were affected by high sulphur prices and affordability issues in end markets, whereas NCB-chain margins improved after China's value-added-tax reversal from April 2026 and better domestic demand.

Which operating ramp-ups are expected to drive growth?

AIL attributes Rs 350-550 crore of potential EBITDA growth to volume and margin ramp-ups, which it describes as on track as planned. The listed levers are ramp-ups in the acid, dichlorobenzene (DCB) and nitrochlorobenzene (NCB) value chains, plus ethylation and NT volumes and selected downstream integration for ethylation products.

AIL says its methyl methacrylate (MMA) capacity expansion has been completed, with volume ramp-up to follow. Fluorination and speciality-chemicals ramp-ups are also in this category, making the planned contribution dependent on several product chains rather than one project.

The application update points to demand conditions in several end markets. AIL reported improved intermediates volumes from demand for advanced polymers in automotive and electronics applications, while pharmaceutical demand was gradually improving and downstream strategic-customer expansions were expected to support volumes.

In dyes, pigments and printing inks, AIL is focused on optimising chain margins and increasing market share. It says higher utilisation of NCB assets has led it to consider capacity expansion, although fluorination margins remained under pressure in the market update.

When will AIL's new projects be commissioned and ramp up?

AIL assigns Rs 300-450 crore of potential EBITDA growth to capital-expenditure-led projects and says all projects in this category are to be commissioned in FY27. The list includes a pilot supporting new-product development, multipurpose plant (MPP) commissioning and ramp-up, Zone 4 commissioning and ramp-up, and the Augene and rearti joint ventures.

Augene, a DCA downstream joint venture with Superform, was under commissioning trials at the time of the presentation. AIL said commercial volumes would begin soon, marketing had started in line with commissioning, and end-application tailwinds could support faster capacity utilisation.

For rearti, AIL said critical equipment for its chemical-recycling-of-plastics project had been delivered and on-ground execution was under way. The company expects commissioning in H2 FY27 and said engagement with potential pyrolysis-oil customers continued.

Zone IV is the main timing milestone in AIL's outlook because the projects are due to commercialise in FY27 and require 18-24 months to ramp up. The FY28 target therefore depends on both FY27 commissioning and the pace at which new assets convert into production volumes.

What markets does AIL intend to develop after commissioning?

AIL says its research and development and MPP facilities will support quicker development, qualification and commercialisation of new advanced chemistries. It also says chlorotoluene commissioning and ramp-up will create opportunities in agro and pharmaceutical business segments.

AIL identifies advanced materials, semiconductors, battery chemicals, defence chemicals and polyurethane additives as adjacent applications it intends to pursue through its existing capabilities. Sustainability, circularity and new energy are also identified as possible new growth platforms, but the presentation does not quantify their FY28 EBITDA contribution.

AIL also plans to use customer relationships and development capabilities for strategic alliances, new product development and contract development and manufacturing organisation services. Its stated areas include agro and pharmaceutical chemistry platforms, fuel additives, flavours and fragrances, and India-based investments with customers.

Conclusion

AIL's FY28 target combines Rs 150-200 crore of cost initiatives, Rs 350-550 crore of volume and margin ramp-ups, and Rs 300-450 crore of capital-expenditure-led growth. EBITDA rose by Rs 188 crore from FY24 to FY26, while the FY28 target implies an increase of Rs 628-1,028 crore from the FY26 result through project commissioning, capacity use and operating measures.

The next disclosed milestones are FY27 commissioning of the capital projects, expected H2 FY27 commissioning for rearti, and the 18-24-month Zone IV ramp-up period. AIL also states a debt-to-EBITDA target below 2.5 times, making commercial volumes, capacity utilisation and project-to-EBITDA conversion the disclosed measures to watch.